OS Therapies Inc
OSTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for OSTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OSTX
OS Therapies Inc (OSTX) is a clinical-stage biotechnology company focused on developing targeted antibody-drug conjugates (ADCs) for oncology, with its lead candidate OST-HER2 in a Phase IIb trial.
Key risk: Cash runway uncertainty
BioSniper Score
Based on 5 of 6 signals
Market Cap
$76.2M
Cash Runway
0.7 moLead Asset
ost-her2 (Phase 2)
Next Catalyst
Phase2_Topline · Sep 1, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 catalyst for OS Therapies Inc.
Similar companies
OS Therapies Inc (OSTX) is a clinical-stage biotechnology company focused on developing targeted antibody-drug conjugates (ADCs) for oncology, with its lead candidate OST-HER2 in a Phase IIb trial.
- Lead product candidate OST-HER2 is being evaluated in a Phase IIb clinical trial for HER2-expressing cancers [sec_mda · as of 2026-03-31].
- As of June 30, 2026, the company reported cash and equivalents of $0.2 million and a net loss of $8.6 million for the quarter [latest financials].
- Accumulated deficit reached approximately $77.4 million as of March 31, 2026 [sec_mda · as of 2026-05-18].
- Research and development expenses increased significantly to $16.4 million in 2025 from $2.8 million in 2024, driven by Phase IIb trial costs [sec_mda · as of 2026-03-31].
What works
- OST-HER2 is advancing in a Phase IIb trial, indicating progress toward potential regulatory submission [sec_mda · as of 2026-03-31].
- The company has a proprietary OST-tADC platform technology that may support future pipeline expansion [sec_mda · as of 2026-03-31].
What to weigh
- Cash position is very low ($0.2M as of June 30, 2026), raising substantial doubt about the ability to fund ongoing operations without additional financing [latest financials].
- The company has a history of significant operating losses and an accumulated deficit of $77.4M as of March 31, 2026, with no product revenue [sec_mda · as of 2026-05-18].
- Shareholders' equity is negative ($-3.3M as of June 30, 2026), indicating financial distress [latest financials].
From the filings
Quoted directly from source documents.
Net loss for the six months ended June 30, 2026 was approximately $19.0 million.
“For the six months ended June 30, 2026 and 2025, we reported a net loss of approximately $19.0 milli”
SEC MD&A · August 14, 2026
Accumulated deficit was approximately $77.4 million as of March 31, 2026.
“accumulated deficit of approximately $77.4 million and $67.2 million, respectively”
SEC MD&A · May 18, 2026
Research and development expenses for 2025 were $16.4 million, driven by Phase IIb trial costs.
“Research and development expenses were approximately $16.4 million for the year ended December 31, 2025”
SEC MD&A · March 31, 2026
Catalyst timeline
- 2026-09-01 · Phase2_Topline · ost-her2 — Phase 2 Readout: ost-her2 — Topline data from the Phase IIb trial of OST-HER2 will be released, which is a key value inflection point for the company.
Risks & what to watch (4)›
Key risks
- Cash runway uncertainty — With only $0.2M cash as of June 30, 2026, the company may need near-term financing to continue operations [latest financials].
- No approved products or revenue — The company has no product revenue and relies entirely on successful development and commercialization [sec_mda · as of 2026-08-14].
- Clinical trial risk — Phase IIb trial outcomes are uncertain; failure could materially impact the company's prospects [sec_mda · as of 2026-03-31].
- Negative shareholders' equity — Shareholders' equity of -$3.3M as of June 30, 2026 indicates financial distress [latest financials].
What to watch
- Phase IIb topline data for OST-HER2 expected on September 1, 2026 [catalyst timeline].
- Any financing or partnership announcements to address the low cash position [latest financials].
- Regulatory interactions and potential submission plans following Phase IIb readout [sec_mda · as of 2026-03-31].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run OS Therapies Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available OS Therapies Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
0.7 months
OCF -$6M · Net income -$9M
Lead: Phase 2
2 candidates
1 upcoming, next in ~2d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Financials
Short Interest
as of May 22, 2026- % of float
- 3.6%
- Days to cover
- 1.7
- Shares short
- 1,384,560
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OSTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for OS Therapies Inc?
OS Therapies Inc (OSTX) is a clinical-stage biotechnology company focused on developing targeted antibody-drug conjugates (ADCs) for oncology, with its lead candidate OST-HER2 in a Phase IIb trial.
What is OS Therapies Inc's lead drug candidate?
OS Therapies Inc's most advanced tracked candidate is ost-her2 (Phase 2) for Osteosarcoma.
What is OS Therapies Inc's next catalyst?
OS Therapies Inc's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: ost-her2" — expected September 1, 2026.
Who is the CEO of OS Therapies Inc?
Mr. Paul A. Romness M.P.H. is the chief executive officer of OS Therapies Inc (OSTX).
Where is OS Therapies Inc headquartered?
OS Therapies Inc (OSTX) is headquartered in Grasonville, MD, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.